Table 1 Photosensitivity reactions to vandetanib reported in the literature
First author, year (Ref.) | Trial design | Vandetanib arm | Control arm | Enrollment no. | Sample size | Underlying cancer |
|---|---|---|---|---|---|---|
Katsuyuki Kiura, 2008 [9] | Phase IIa | 100-300 mg/day | N/A | 53 | 12 | NSCLC |
Heidi Kong, 2009 [11] | N/A | N/A | N/A | N/A | 1 | Recurrent brain tumor |
Chih-Hsiang Chang, 2009 [10] | Phase II | 300 mg/day | N/A | N/A | 1 | HCC |
Damien Giacchero, 2012 [12] | Phase II/III | 300 mg/day | Placebo | 63 | 23 | Metastatic thyroid cancer |